FDA accepts VIVUS’s NDA application for Avanafil
According to VIVUS, Inc. (NASDAQ: VVUS), the company’s new drug application (NDA) for avanafil, an experimental drug candidate intended to
Read moreavanafil
FDA acknowledges Vivus’s application for Avanafil
MOUNTAIN VIEW, Calif. (AP) — According to an announcement by drugmaker Vivus Inc., the FDA will take until April 29,
Read more